SYNTIS BIO
Live / Applied — First extension granted (statement of use) (as of 10 Sept 2026)
What this means for you
Not registered yet, but its 20 Jun 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99245108
- Mark type
- Stylized text
- Filed
- 20 Jun 2025
- Published for opposition
- 03 Mar 2026
- Attorney of record
- Sara M. Bauer
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of metabolic diseases and disorders; Pharmaceutical preparations for the treatment of weight gain and obesity; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, and degenerative conditions associated with aging; Pharmaceutical preparations for the treatment and prevention of chronic diseases, conditions, and functional disorders, namely, Alzheimer's Disease, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, metabolic diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases; Pharmaceutical preparations for the treatment and prevention of chronic metabolic diseases, metabolic conditions, and functional neurological disorders; Biological preparations for the treatment of metabolic diseases and disorders; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents
Owner
- Syntis Bio, Inc., Boston, MA, US
- Syntis Bio, Inc., Boston, MA, US
Prosecution history
- 11 Sept 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 Sept 2026 — SOU EXTENSION 1 GRANTED
- 10 Sept 2026 — SOU EXTENSION 1 FILED
- 10 Sept 2026 — SOU TEAS EXTENSION RECEIVED
- 28 Apr 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 03 Mar 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 03 Mar 2026 — PUBLISHED FOR OPPOSITION
- 25 Feb 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 10 Feb 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 09 Feb 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 09 Feb 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 09 Feb 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 10 Nov 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 10 Nov 2025 — NON-FINAL ACTION E-MAILED
- 10 Nov 2025 — NON-FINAL ACTION WRITTEN